COVID-19 Information Center
- Coronavirus disease
COVID-19 Information Center
Novartis is responding to coronavirus disease (COVID-19) with safety of associates and patients globally our primary concern. We are also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines. This information center provides a central hub for updates, guidance and other resources.
Novartis response to COVID-19
In the face of a global crisis, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to address the coronavirus disease pandemic.
Choice with Responsibility: Reimagining how we work
Novartis now offers associates the choice to decide how, where and when they work to create the greatest impact for their role while taking personal responsibility to inform managers and align with teammates for effective collaboration, based on the nature of their work.
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
Our industry is at an inflection point. Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
Sandoz responds to increased demand for antibiotics and other essential medicines for patients during COVID-19
Going the extra mile to keep clinical trials on track during the COVID-19 pandemic
A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.
Novartis COVID-19 Response Fund
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
Leader perspectives during COVID-19
A mini-video-series in which Novartis leaders connect on video calls to discuss some of the biggest questions for healthcare as we navigate the global pandemic.
Pharma’s pandemic response could help attract tech talent
Novartis Chief Digital Officer Bertrand Bodson talked to FiercePharma about pharma’s COVID-19 pandemic reputation boost with potential tech hires.
Developing drugs during a pandemic
Novartis CEO Vas Narasimhan spoke with WIRED’s Steven Levy and shared his perspective on some of the ways forward for the industry and the world.
